Chronic Lymphocytic Leukemia Clinical Trial
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
Summary
The purpose of this study is to evaluate the safety and effectiveness of ONTAK in previously treated patients with leukemia-cll/" >chronic lymphocytic leukemia (CLL)
Eligibility Criteria
Inclusion Criteria:
Patients with B-cell Chronic Lymphocytic Leukemia, Rai Stage 0-II with indication for treatment by NCI Working Group Criteria or Rai Stage III or IV.
Patients must have received at least one prior purine analogue-based chemotherapy regimen.
ECOG Performance Status of 0, 1, or 2.
Female patients cannot be pregnant and must use birth control during the course of the study and for three weeks after the study ends.
Exclusion Criteria:
Prior treatment with ONTAK (DAB389IL-2) or DAB486IL-2.
Received any therapy for CLL within 35 days prior to study entry.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 14 Locations for this study
Fountain Valley California, 92708, United States
La Jolla California, 92093, United States
Chicago Illinois, 60612, United States
New York New York, 10021, United States
Houston Texas, 77030, United States
Mendoza , 5500, Argentina
East Melbourne Victoria, 3002, Australia
Frankston , 3199, Australia
Goiania GO, 74605, Brazil
Curitiba PR, 80060, Brazil
Rio de Janeiro RJ, 21941, Brazil
Barretos SP, 14784, Brazil
Sao Paulo SP, 05403, Brazil
Montreal Quebec, H3T 1, Canada
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.